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Abstract
Background: Prostate cancer is the most common non-cutaneous malignancy in men. Today most patients may
expect to live years following the diagnosis and may thus experience significant morbidity due to disease
progression and treatment toxicity. In order to address some of these problems exercise has been suggested and
previously studies have shown improvements of disease specific quality of life and a reduction in treatment-related
toxicity. Cohort studies with long term follow up have suggested that physical activity is associated with improved
survival in prostate cancer patients. Previously one randomised controlled trial has examined the efficacy of football
in prostate cancer patients undergoing androgen deprivation therapy to usual care and reported positive effects on
lean body mass and bone markers. Against this background, we wish to examine the effectiveness of community-
based football for men diagnosed with prostate cancer.
Methods: Using a randomised controlled parallel group, multicenter, superiority trial design, two hundred prostate
cancer patients will be recruited and randomised (1:1) to either community-based football one hour twice weekly
or to a control group. The intervention period will be six months. The primary outcome is quality of life assessed
after 12 weeks based on the change from baseline in the Functional Assessment of Cancer Therapy–Prostate
questionnaire. Secondary outcomes are change from baseline to six months in quality of life, lean body mass, fat
mass, whole body and regional bone markers, as well as physical activity and functional capacity at 12 weeks and
six months. Safety outcome variables will be falls resulting in seeking medical assessment and fractures during the
six-month period.
Discussion: Football is viewed as a case for non-professional, supervised community-based team sport for promoting
long-term physical activity in men diagnosed with prostate cancer. This randomised trial will provide data on
effectiveness and safety for men with prostate cancer when football training is delivered in local football clubs.
Trial registration: Clinicaltrials.gov identifier: NCT02430792
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Background
Prostate cancer (PCa) is the most frequently diagnosed
non-cutaneous cancer in men worldwide [1]. In com-
parison to most other malignant diseases, PCa pro-
gresses slowly. Presently more than 90 % of all cases of
PCa are detected early, with the 10 and 15-year relative
survival rates at 98.8 and 94.3 %, respectively [1]. How-
ever, treatment of PCa is often associated with side
effects and as the patients are likely to survive many
years following diagnosis and primary treatment, quality
of life (QoL) is of growing interest. PCa patients
managed with hormonal therapy face an elevated risk
of becoming overweight and for developing metabolic
syndrome, type 2 diabetes and cardiovascular disease
[2], which regular physical activity may counteract.
Despite this fewer than half of men living with PCa
follow the official physical activity guidelines [3]. More-
over, unlike many other cancer patient groups, PCa
patients do not change their health behaviour spontan-
eously after being diagnosed [4]. Cohort studies exam-
ining the relationship between physical activity and
disease progression and survival in men with PCa have
shown that vigorous activity is associated with better
outcomes [5–7].
Recent systematic reviews of exercise intervention tri-
als in men with PCa indicate that exercise has a benefi-
cial effect on muscular fitness, cardio-respiratory fitness,
functional task performance, lean body mass (LBM),
fatigue and QoL [8–10]. Furthermore exercise has been
shown to meet the requests male cancer patients have
for active, rational activities [11, 12]. The vast majority
of existing trials, however, have examined the effects of
hospital-based, short-term and cost-intensive exercise
interventions with a short follow-up period and low
degree of adherence [13]. Therefore the long-term ef-
fects and applicability of interventions promoting phys-
ical activity remain undocumented [14].
Participation in sport is acknowledged as important
for public health [15]. The most common sport for
men in Denmark and many other countries is football
[16]. Growing evidence suggests that recreational foot-
ball, i.e. non-tournament-based small-sided games, can
have significant health promoting effects in various popu-
lations [17–19]. It has also been shown that football may
provide peer-to-peer psychosocial support and improve
social capital [20], potentially increasing long-term adher-
ence. Therefore, we recently examined the efficacy of
recreational football in men with PCa undergoing andro-
gen deprivation therapy (ADT). The results show that the
football training improved LBM, muscle strength and
markers of bone strength [21, 22] and that men experi-
ence football as an opportunity to regain control and
responsibility for their own health without being in the
role of patient [23].
Usual care for men with PCa in Denmark is re-
habilitation (often aerobic and/or strength training)
offered by local authorities. However, substantially
fewer men than women (30 vs. 70 %) participate in
rehabilitation [24], indicating that rehabilitation efforts
might should be gender-oriented [25]. In this study,
the participants in the control group are informed of
the official physical activity guidelines and advised to
continue their daily living, as they normally would do,
not guiding them to other interventions neither pre-
venting them to do so.
Thus, we will examine if recreational football, deliv-
ered in local football clubs (i.e. community-based),
may complement existing rehabilitation approaches by
promoting adherence to exercise and improving QoL
and physiological health measures.
Objective
The primary objective of the FC Prostate Community
Trial (FCPC) trial is to determine whether community-
based football is superior to usual care for improving
cancer-specific QoL after 12 weeks of participation.
The secondary objectives are to determine whether
community-based football is superior to usual care for
improving PCa-specific QoL, lean body mass, fat mass,
bone mineral density and bone mineral content after six
months and functional well-being and physical activity
after 12 weeks and after six months. The safety of the
intervention will also be evaluated based on falls result-
ing in seeking medical assessment and fractures after six
months.
Methods
Trial design
The FCPC Trial is a randomised controlled parallel-
group superiority trial with two parallel groups (com-
munity-based recreational football and usual care) that
examines QoL after 12 weeks as the primary endpoint.
Participants will be randomised (1:1) and the trial
design is pragmatic [26].
Participants
Patients age 18 years or older diagnosed with PCa, able
to read and write Danish and willing to sign an informed
consent are eligible for participation in the study.
Patients cannot be included if they have undergone
prostatectomy within six weeks prior to participation,
are prohibited from participating in football training by
their primary physician or have a hip or spine BMD T-
score lower than −2.5 (i.e. the criterion for osteoporosis).
Table 1 lists the eligibility criteria.
Patients will be recruited from urological clinics, which
will provide information on the study and promote
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patients to participate in the study. Figure 1 presents a
timeline for participation and the trial design.
Study sites and recruitment status are available at clinical-
trials.gov under trial registration number NCT02430792.
The football intervention
Participants allocated to the intervention group will be
offered one hour of recreational football twice weekly.
The football training sessions consist of a 20-min warm-
up based on the FIFA11+ concept, though modified to
suit older players [27]. Next, participants will spend
20 min practising dribbling, passing and shooting. The
training sessions will then end with 20 min of 5–7-a-side
football. Two coaches recruited from the local football
club will be in charge of all training sessions. The
coaches are expected to have experience as either a
player or coach but no other formal qualifications are
required. The coaches will be required to have passed a
first-aid course and to complete a 10-h course involving
lectures on PCa treatment, patient experiences of PCa
and a manual describing the content of the training,
including the FIFA 11+ concept intended to prevent
injuries. Participants will be told to avoid hard tackles
and other actions that carry a risk of injury. In the event
of injuries participants will remain in their allocated
group and will be encouraged to participate in football
practice again after recovery. Adherence to the interven-
tion will be recorded by the coaches. Participants
allocated to football training will be able to track their
individual adherence and compare it to an average
adherence rate of participants in the football group. A
logical model, presented in Table 2, summarises the key
inputs, activities and intended outputs of the interven-
tion, while Fig. 2 presents the activities and Fig. 3 shows
the assumed causal pathways for the effect of the inter-
vention on the individual.
Control group
Participants allocated to the control group will receive
a phone-based counselling session (5–15 min) as part
of the information on group allocation, as well as
information via email on the current physical activity
guidelines.
Outcomes
The primary outcome is change in PCa-specific QoL from
baseline to 12 weeks measured with the fourth version of
the Functional Assessment of Cancer Therapy–Prostate
(FACT-P) questionnaire [28], a self-reported, multidimen-
sional QoL instrument specific for PCa patients [29]. The
questionnaire consists of 27 general cancer items covering
four domains - physical, social/family, emotional and
functional well-being - supplemented with 12 specific
PCa-related items. All items are scored on a 0–4 Likert
scale. The total FACT-P score ranges from 0 to 156,
higher scores indicating higher QoL.
Table 3 presents all outcomes with specified measure-
ment variable, analysis metric, method of aggregation
and time point.
The 12-Item Short Form Health Survey (SF-12) and
EQ-5D-5 L, a standardised instrument by EuroQol for
use as a measure of health outcome, will be collected for
use in later economic evaluations of the intervention.
Table 1 Eligibility criteria
Inclusion Exclusion
• Patients diagnosed with
prostate cancer
• Age: ≥18 years
• Able to read and complete
questionnaires in Danish
• Signed informed consent
• < 6 weeks prostatectomy
• Football training not allowed by
primary physician
• Hip or spine bone mineral
density < −2.5 T-score
Fig. 1 Trial design and timeline
Bjerre et al. BMC Cancer  (2016) 16:767 Page 3 of 10
Sample size and power considerations
The sample size calculation is based on the detection of a
minimal clinical important difference between groups on
six points on the FACT-P questionnaire [28] at 12 weeks
with a standard deviation of 15 FACT_P points. A two-
sided significance level of 5 % and power of 80 % were
chosen; The standard deviation is based on a previous
exercise trial [30] but increased slightly as FCPC partici-
pants will be more heterogeneous than the participants in
that trial. Consequently, 100 participants will be needed in
each group, i.e. 200 participants in total, in order to de-
tect a statistically significant difference between groups.
No interim analysis will be performed. However, if the
anticipated sample size has not been enrolled by 1 May
2017, recruitment will end and final analyses will be
performed with the number of patients recruited at
that point.
Randomisation
Sequence generation, the allocation of participants, will
be done using a computer-generated list of random
numbers. The allocation will be stratified by center and
by androgen deprivation status (yes/no) with a 1:1 allo-
cation using random block sizes. A statistician not
involved in the trial uploaded all the allocation se-
quences in the trial management system. The eligibility
Table 2 Logic model: The FCPC Trial
Inputs (resources) Activities Outputs Outcomes
(short-term)
Impacts
(long term)
Financial resources
• Funding
Human resources
• Urologist and urological
nurses
• Local experienced football
coaches
Products
• Football-training manual
• Disease specific football-coach
education
• Tablet based app to register
attendance and field-test
performance
• Collaboration with local
football clubs
• Education of local coaches
• Collaboration with urological clinics
• Information to clinical staff and
patients' on the possibilities of
referral for the study
• Provision of feedback on
attendance and progress
(field tests)
• Prostate cancer patients
referred to and participating
regularly in football training
Improved:
• Quality of life
• Physical activity
level
• Fat mass
• Muscle mass
• Bone mineral
density and content
• Functional well-being
• Dyadic adjustment
Improved:
• Survival
Reduced:
• Co-morbidities
• Hospital
admissions
• Medication usage
Planned work Intended Results
Fig. 2 Action theory. The trial involves two major activities: (a1) education/training of non-professional football coaches recruited from local sports
clubs delivering the intervention and (a2) education of clinical hospital staff (primarily nurses) with the authority to refer prostate cancer patients
to supportive care interventions. These two major activities are expected to produce: (b1) delivery of community-based football training adapted
to men with prostate cancer and (b2) continuous referral of men with prostate cancer to the trial. As still more men with prostate cancer are
expected to be referred from the clinic, the assumption is that the number of men with prostate cancer participating in community-based
football will increase (b2→ b1). The expectation is that these men will share what they think of the intervention with the medical team/staff and
as such contribute to the further education of the clinical staff (b1→ a1)
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of participants will be assessed by either investigators or
project nurses at each center. The randomisation will be
performed centrally by researchers at the University
Hospitals Centre for Health Research, Copenhagen
University Hospital, Rigshospitalet.
Allocation concealment will be implemented, as the
allocation sequence will be hidden from the researchers
and, using web-based trial management, no one other
than the statistician who uploads the random number
lists have access to the lists.
Fig. 3 Assumed causal pathways
Table 3 Outcomes with specified measurement variable, analysis metric, method of aggregation and time point
Concept Specific measurement variable Patient- level
analysis metric
Method of
aggregation
Time point(s)
Primary outcome
Quality of life Functional Assessment of Cancer
Therapy - Prostate Questionnaire
Change from baseline Mean 12 week
Secondary outcomes
Quality of life Functional Assessment of Cancer
Therapy - Prostate Questionnaire
Change from baseline Mean 6 month
Muscle mass Whole-body lean body mass Change from baseline Mean 6 month
Fat mass Whole-body fat mass Change from baseline Mean 6 month
Whole body bone strength Whole-body bone mineral content Change from baseline Mean percent 6 month
Whole-body bone mineral density Change from baseline Mean percent 6 month
Self-reported physical activity International Physical Activity Questionnaire Change from baseline Mean 12 week and 6 month
Functional well-being Subscale from Functional Assessment of
Cancer Therapy-Questionnaire
Change from baseline Mean 12 week and 6 month
Regional bone strength Lumbar spine bone mineral density Change from baseline Mean percent 6 month
Femoral neck bone mineral density Change from baseline Mean percent 6 month
Total hip bone mineral density Change from baseline Mean percent 6 month
Safety Participants with any fracture Number in each group Proportion 6 month
Participants with falls that resulted in seeking
medical assessment
Number in each group Proportion 6 month
Exploratory outcomes
Dyadic adjustment DAS-7 Change from baseline Median 12 week and 6 month
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Blinding
Lean body mass, fat mass, bone mineral density and
bone mineral content outcomes measured with dual-
energy X-ray absorptiometry (DXA) at six months will
be performed by an external assessor blinded to group
allocation. It is not possible to blind participants or staff
due to the nature of the intervention.
The analyses will be performed with the group identity
blinded and the groups denoted as A and B. Blinded
analyses of both the primary and secondary outcomes
will be presented to the research group and decisions on
the abstract and the conclusion for the main publication
will be made before revealing group identity.
Data collection
A web-based trial data management system (easytrial.net)
will be used to collect data on the primary outcome, FACT-
P and the other self-reported outcomes (International Phys-
ical Activity Questionnaire (IPAQ), seven-item Dyadic
Adjustment Scale, SF-12 and EQ-5D-5 L), in addition to
demographic characteristics at baseline. The web-based
trial data system will distribute questionnaires and invita-
tions to DXA scans according to the date for randomisa-
tion. The trial data system will send a unique e-mail to
each trial participant’s personal e-mail address. Applied
to both groups, this procedure will ensure that re-
sponses are unaffected by an interviewer or changing
conditions. Participants will be asked to complete ques-
tionnaires 12 weeks and six months after randomisation,
and come to a six-month DXA assessment, even if they
discontinue the allocated treatment. Non-adherence to
the allocated intervention is thus not necessary off study,
and participants will still be encouraged to do follow-up
assessments.
DXA scans will be used to collect data on body
composition: LBM and fat mass, and bone markers:
bone mineral content (BMC) and bone mineral density
(BMD). Data accuracy will be ensured, as participants
will add questionnaire responses directly into the trial
data system, while DXA outcomes extracted from DXA
scanners will also be directly added into the trial data
system. The trial data system adheres to the International
Council for Harmonisation Guideline on Good Clinical
Practice (ICH-GCP) and the Danish data protection legis-
lation. Figure 1 provides time points for data collection,
study visits, enrolment, intervention and assessments.
Statistical methods
Plan for statistical analyses
The primary statistical analysis targets the effect on PCa
specific QoL of a treatment policy offering community-
based football to men with PCa. In particular, patients
will be analysed in the treatment group to which they
were randomly allocated according to the intention-to-
treat principle. The appropriate method for addressing
this effect will depend on the assumptions made about
missing data (dropouts). Our main analysis is valid
under the missing at random assumption but we will
also present sensitivity analyses robust to non-ignorable
patterns among patients with incomplete data.
Per protocol analyses will be performed to estimate the
de jure effect of the treatment for compliant patients. The
per protocol population will be defined as intervention
group participants who attended the football intervention
at least 12 times in the first 12 weeks and 24 times in the
six-month intervention period.
Significance tests will be two-sided with a maximal
type I error risk of 5 %. To address the problem of
multiple comparisons for secondary analyses when
several outcomes are tested or multiple constracts are
extracted from the same statistical model, p-values will
be adjusted using the step-down Bonferroni method of
Holm [31] or appropriate modern alternatives.
Trial profile
A CONSORT diagram will show trial participant flow.
The number of screened patients, the patients who meet
the inclusion criteria and trial subjects included in
analyses will be reported together with reasons for
exclusion of trial subjects.
Primary outcome
The continuous FACT-P outcome score will be calcu-
lated using the official scoring guideline. As described in
the scoring guideline missing items will be prorated by
multiplying the sum of the subscale with the number of
the items in the subscale, then divided by the number of
items answered. This will be done if more than 50 % of
the items are answered in the subscales and 80 % are
answered in the total questionnaire. The change score of
the total FACT-P at 12 weeks will be calculated by
subtracting the total 12-week score from the respective
trial participant’s baseline score. Analysis of covariance
will be used [32], group and ADT status will be set as
factors, the response will be change in FACT-P and
covariates will be age and baseline score. The results will
be presented as least squares means (LSMEANS) differ-
ences between the two groups with 95 % confidence
intervals and p-values.
Secondary outcomes including safety outcomes
Changes from baseline to six months for LBM, BMD,
BMC and total body fat mass will be analysed in the
same manner as the primary outcome.
QoL, functional well-being and physical activity (based
on metabolic equivalent of task values derived from
IPAQ) measured at baseline, 12 weeks and six months
will be analysed using a mixed model for repeated
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measurements. Changes from baseline to 12 weeks or
six months will be treated as the response. The model
will include fixed effects of factors: group, ADT, sam-
pling time and their interactions, and the analysis will be
adjusted for age and baseline value. The correlation
between measurements on the same participant will be
modelled using a random effect of participant.
Safety outcomes will be listed for each group and the
number of falls that resulted in seeking medical assess-
ment and fractures will be compared across groups
using Fisher's exact test.
Subgroup analyses will be reported for the patients
treated with ADT, which means that results will be given
for both the overall treatment effect and for the
subgroup obtained by stratifying according to ADT. To
verify the credibility of our subgroup analyses, we will
apply the criteria proposed by Sun and colleagues [33],
i.e. the subgroup variable is a baseline characteristic, a
stratification factor, specified a priory and includes only
a small number of analyses.
Outline of figures and tables
The first figure in the main publication will be a CON-
SORT diagram and the second figure will illustrate
changes in the primary and secondary outcomes, with
the exception of safety outcomes, at 12 weeks and six
months, according to treatment group.
A third figure will display mean curves for the primary
outcome for participants in different groups according
to the pattern of missing data. In particular, mean curves
will be shown separately for completers and participants
with missing data at one or more assessment times. The
figure will be used to guide the type of sensitivity ana-
lyses performed to adjust results for a potentially deviat-
ing pattern for patients with incomplete observations.
The main publication will also include three tables,
one delineating the characteristics of trial subjects, one
showing changes in primary and secondary outcomes at
12 weeks and at six months, and one presenting safety
outcomes according to group and type.
Ethics
The Ethics Committee for the Capital Region of
Denmark (file number H-2-2014-099) and the Danish
Data Protection Agency has approved the trial and the
trial is registered at clinicaltrials.gov: NCT02430792.
Any changes to the protocol that influence the conduct
of the study, affect the safety or benefits for participants,
i.e. study objectives, study design, eligibility criteria and
study procedures, will be documented in protocol amend-
ments, which must be approved by the Ethics Committee
for the Capital Region of Denmark and which will be
reported when the study is disseminated.
Patients will receive written and oral information
about the study. Project nurses or researchers with
suitable training will obtain informed consent based on
the standard operating procedure. Consent will be ob-
tained prior to any study activities and study participants
can withdraw from the trial at any time without any
explanation or consequences. Although aware that they
are under no obligation to provide an explanation, indi-
viduals who withdraw will be asked why they chose to
discontinue the trial.
Discussion
The FCPC Trial is a randomised, controlled, parallel-
group trial examining the effectiveness of community-
based football on QoL in men with PCa.
Whether exercise should be an integral part of treat-
ment for PCa is under debate [34, 35]. The effects of
exercise on side effects of treatment has been shown
[36, 37]. However, previous exercise trials for men with
PCa reporting positive effects had short follow ups
and took place in clinical settings, thus not utilising
community-based structures for sport and exercise.
The FCPC Trial will provide empirical data on
whether local sport clubs are possible venues for clin-
ical health promotion through a team-based exercise
intervention. With experience from this study, we hope
to gain further insight into the effects in a real-world
setting and, through subgroup analyses, confirm find-
ings from a previous study on PCa patients undergoing
ADT [21].
Since numerous men currently live many years with
PCa, it has been recommended that the disease be con-
sidered similar to other chronic diseases [38]. With this
in mind, issues affecting QoL are of primary concern,
not just for the patient but also for the treating urologist,
who is often the primary treating physician [39]. We
argue that football training is a supportive intervention
where short-term QoL is of primary concern both for
the patient and in the context where long-term adher-
ence is a prerequisite for maintaining physiological bene-
fits. In a recent review on supportive interventions
designed to improve QoL for men with PCa, FACT-P
was most frequently used to measure QoL [39]. Other
instruments, such as the EORTC Quality of Life Ques-
tionnaire–Prostate Module (QLQ-PR25) or generic
health-related QoL measurements like the Short-Form
36 Health Survey, are possible alternatives. Our aim,
however, is to employ a prostate-specific, validated and
frequently used QoL instrument to enhance comparabil-
ity and validity, which is why we have chosen to use
FACT-P for the primary outcome.
Large trials examining exercise interventions for im-
proving QoL in cancer patients have been shown to be
at risk of bias in a number of domains [40], e.g. selection
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bias and attrition bias due to unclear allocation conceal-
ment and incomplete outcome data. It has been argued
that one of the barriers preventing decisions-makers from
supporting this kind of intervention is that exercise
science is not of the same calibre as other fields of medical
science [41]. Due to the nature of non-pharmacological
interventions, blinding often proves impossible [42] but
that does not prevent behavioural studies from adhering
to the majority of the ICH-GCP principles. The present
study will adhere to these principles in order to conduct a
high trial with enhanced comparability with medical drug
trials while simultaneously preventing outcome reporting
bias and erroneous interpretations of post-hoc analyses.
A key aim of the FCPC Trial is to generate scientific
knowledge to help support decisions on whether to use
football in community-based clubs as a strategy for
promoting health in men with PCa. For that reason the
trial has utilised the PRECIS-2 wheel [43] to help define
the pragmatic approach of the various domains, as
shown in Fig. 4. The study was designed with this in
mind and the recruitment of participants in multiple
centres and delivery of the intervention in the commu-
nity were chosen in order to enhance the generalisability
of the results [26].
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